CommentaryThe promise of treatment as prevention for hepatitis C: Meeting the needs of people who inject drugs?
Section snippets
The promise of treatment as prevention for HCV
We are in the midst of a changing HCV treatment landscape. Oral direct-acting antivirals (DAAs) have cured up to 100% of clinical trial participants from HCV, fuelling considerable optimism in the sector (Afdhal et al., 2014, Sulkowski et al., 2014). References to HCV eradication and elimination are now commonplace (Grebely and Dore, 2014, Ryder and Dillon, 2014). One key strategy in the HCV elimination toolbox is TasP. HCV TasP involves prioritisation and scale up of HCV treatment provision to
The limits of a population-based approach
TasP for HCV, as with HIV, has implications for clinical treatment decision-making and for the way health systems prioritise and target treatment provision. This has become a particularly fraught issue since the development and licencing of expensive DAAs. In the context of potential cost-justified rationing of DAAs in the UK, Innes, Goldberg, Dillon, and Hutchinson (2014) project that the prioritisation of treatment for PWID will optimally impact on transmission incidence (a TasP approach),
Needs of PWID in future HCV care
High HCV treatment interest and willingness has been evidenced among PWID, even in a context of interferon-based therapy provision (Canfield et al., 2010, Doab et al., 2005). International clinical guidelines increasingly recommend treatment assessment and access for people who are currently injecting (European Association for the Study of the Liver, 2014). Yet HCV treatment access and uptake is suboptimal worldwide – especailly for PWID (Martin, Vickerman, et al., 2013). Barriers to treatment
What can we learn from HIV?
The HIV field illustrates the multiple social structural barriers to ART treatment uptake and adherence for PWID (Milloy et al., 2012). There has been a dearth of prospective studies addressing the efficacy of TasP for PWID, despite findings by Wood et al. (2009) that community viral load, over and above condomless sex or syringe sharing, is predictive of HIV incidence. HIV TasP for PWID at best remains a concept – with ART access and uptake among this population woefully inadequate, at only 4%
Conclusion
It is well evidenced that PWID are interested in HCV treatment and have comparable adherence and SVR rates to other groups. Clinical guidelines are increasingly recommending HCV treatment assessment and access for PWID, yet provider reluctance to refer and treat is common. DAAs have revolutionised HCV treatment options, however these more efficacious drugs are unlikely to be available for all. In this context HCV TasP has the potential to be a powerful advocacy tool. Modelling work has
Conflict of interest
The authors have no conflicts of interest to declare.
Acknowledgements
Thank you to Jude Byrne, AIVL, for your input into ongoing TasP discussions. Thank you also to the three anonymous reviewers for your encouraging and helpful suggestions. This article builds on a brief discussion piece published in Lazarus et al., 2014 and draws on qualitative data from the NIHR funded Hepatitis C Treatment Journey Study. Magdalena Harris is funded by an National Institute of Health Research postdoctoral fellowship [NIHR-PDF-2011-04-031].
References (69)
- et al.
Obstacles in provision of anti-retroviral treatment to drug users in Central and Eastern Europe and Central Asia: A regional overview
International Journal of Drug Policy
(2007) - et al.
Can hepatitis C virus infection be eradicated in people who inject drugs?
Antiviral Research
(2014) - et al.
Treatment as prevention and cure towards global eradication of hepatitis C virus
Trends in Microbiology
(2013) - et al.
Taming systems to create enabling environments for HCV treatment: Negotiating trust in the drug and alcohol setting
Social Science & Medicine
(2013) - et al.
Injecting practices in sexual partnerships: Hepatitis C transmission potentials in a ‘risk equivalence’ framework
Drug and Alcohol Dependence
(2013) - et al.
Patient-important benefits of clearing the hepatitis C virus through treatment: A simulation model
Journal of Hepatology
(2014) - et al.
People who use drugs, HIV, and human rights
The Lancet
(2010) - et al.
Social and structural determinants of HAART access and adherence among injection drug users
International Journal of Drug Policy
(2010) - et al.
HIV prevention, treatment, and care services for people who inject drugs: A systematic review of global, regional, and national coverage
The Lancet
(2010) - et al.
The end of hepatitis C
Clinical Gastroenterology and Hepatology
(2014)
How to build trustworthy hepatitis C services in an opioid treatment clinic? A qualitative study of clients and health workers in a co-located setting
International Journal of Drug Policy
Factors associated with hepatitis C knowledge among a sample of treatment naive people who inject drugs
Drug and Alcohol Dependence
Human rights and access to hepatitis C treatment for people who inject drugs
Int J Drug Policy
Epistemic fault lines in biomedical and social approaches to HIV prevention
Journal of the International AIDS Society
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection
New England Journal of Medicine
Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS Study
Clinical Infectious Diseases
Treatment of hepatitis C virus infection among people who are actively injecting drugs: A systematic review and meta-analysis
Clinical Infectious Diseases
Articulating a rights-based approach to HIV treatment and prevention interventions
Current HIV Research
The everyday violence of hepatitis C among young women who inject drugs in San Francisco
Human Organization
Models of care for the management of hepatitis C virus among people who inject drugs: One size does not fit all
Clinical Infectious Diseases
Methadone maintenance patients’ knowledge, attitudes, beliefs, and experiences concerning treatment for hepatitis C virus infection
Substance Use and Misuse
Estimated HIV incidence in the United States, 2007–2010
HIV Surveillance Supplemental Report
CDC's new high-impact approach to HIV prevention funding for health departments
Prevention of HIV-1 infection with early antiretroviral therapy
New England Journal of Medicine
The funding crisis for harm reduction
Peer support models for people with a history of injecting drug use undertaking assessment and treatment for hepatitis C virus infection
Clinical Infectious Diseases
Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia
Clinical Infectious Diseases
Counterpublic health and the design of drug services for methamphetamine consumers in Melbourne
Health
Treatment of hepatitis C as prevention: A modeling case study in Vietnam
PLoS ONE
EASL recommendations on treatment of hepatitis C 2014
Harm reduction and hepatitis C: On the ethics and politics of prevention and treatment
Addiction Research & Theory
Socially-integrated transdisciplinary HIV prevention
AIDS and Behavior
Hepatitis C treatment access and uptake for people who inject drugs: A review mapping the role of social factors
Harm Reduction Journal
The future of hepatitis C care: Taking PWID needs and perspectives into account
Cited by (24)
Has the HCV cascade of care changed among people who inject drugs in England since the introduction of direct-acting antivirals?
2024, International Journal of Drug PolicySocioeconomic stability is associated with lower injection frequency among people with distinct trajectories of injection drug use
2021, International Journal of Drug PolicyCitation Excerpt :For PWID unable or unwilling to completely stop, reducing the frequency of injection may be an achievable target, and is a favorable interim alternative because of the diminished risks of injection-related harms (Bruneau et al., 2011; Bruneau, Roy, Arruda, Zang, & Jutras-Aswad, 2012; Hope, Kimber, Vickerman, Hickman, & Ncube, 2008; Islam et al., 2019). At a time when the importance of creating enabling environments to minimize harms among PWID is increasingly emphasized (Harris, Albers & Swan, 2015; McNeil & Small, 2014; Rhodes, 2009; Strathdee et al., 2010), this study seeks to refine our understanding on the impact of these two modifiable factors on injection drug use. Our aims were (i) to characterize long-term trajectories of injection drug use in a sample of active PWID living in Montréal and (ii) to examine how housing and income stability relate to injection frequency among PWID with diverse longitudinal injection patterns.
Conceptualising access in the direct-acting antiviral era: An integrated framework to inform research and practice in HCV care for people who inject drugs
2019, International Journal of Drug PolicyCitation Excerpt :For simplicity of presentation, this process is not included in Table 1. However, we note its consistency with the findings of numerous studies of HCV care in PWID, which have tied widespread experiences of stigmatisation and discrimination in health services to the receipt of inadequate care (Brener et al., 2015; Harris, 2005; Harris, Albers, & Swan, 2015; Harris & Rhodes, 2013; Harris et al., 2013; Lang et al., 2013; Treloar & Rhodes, 2009; Zickmund et al., 2004). These experiences are internalised, shape expectations of future treatment, reinforce mistrust in health services, and can drive avoidance and delays in care seeking (Biancarelli et al., 2019, 2749).
Transitioning from interferon-based to direct antiviral treatment options: A potential shift in barriers and facilitators of treatment initiation among people who use drugs?
2019, International Journal of Drug PolicyCitation Excerpt :Nonetheless, an international study of clinicians found that only 15% were willing to prescribe these medications to active PWID, with willingness inversely related to injection frequency (Asher et al., 2016). Our findings suggest that current strategies continue to exclude individuals whose drug use is not medically stabilized, including stimulant users and those injecting with high frequency (Harris, Albers, & Swan, 2015). These are individuals with substantially elevated risk of HCV transmission (Bruneau et al., 2012) and innovative strategies, such as the integration of care systems within supervised injection sites (Høj, Minoyan, Artenie, Grebely, & Bruneau, 2018) or social network strategies to referral and treatment (Hellard et al., 2014) may be required.
Care, agency and criminality: Making sense of authorised extended distribution in the accounts of key stakeholders
2019, International Journal of Drug PolicyCitation Excerpt :In relation to HIV, the TasP strategy has attracted sustained criticism for its over-emphasis on biomedical responses the detriment of social and behavioural responses, and for its focus on HIV-positive over HIV-negative individuals (Adams, 2011; Kippax, 2012). Harris, Alber, and Swan (2015) draw convincing comparisons to hepatitis C and argue that the promise of DAA is a biomedical and population-health response that is more appealing to policy makers than human-rights responses, and that this biomedical emphasis and the costs associated with it threatens resources for primary prevention and harm reduction, including the introduction of NSP innovations such as extended distribution. Indeed, in a setting where biomedical solutions are seen to be achievable, there is much less enthusiasm for seeking the authorisation of extended distribution which would require difficult legislative changes.
Caring and curing: Considering the effects of hepatitis C pharmaceuticalisation in relation to non-clinical treatment outcomes
2018, International Journal of Drug PolicyCitation Excerpt :The image of DAAs as the pharmaceutical solution to the social problem of HCV acts to reposition those most-at-risk and most marginalised from care as critical to potentiating elimination impact at the population level. An elimination agenda rehabilitates PWID as a treatment priority population; but in relation to their potential as HCV ‘transmitters’, rather than as individuals deserving of care (Fraser & Moore, 2011; Harris, Albers, & Swan, 2015). Interferon-era research makes an alternative case for treatment access – illustrating the transformative potentials of HCV treatment for individuals, over and above population-based measures of morbidity, mortality and transmission reduction.